OTCMKTS:MVRBFMedivir AB (publ) Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medivir AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.58 0.00 (0.00 %) (As of 05/22/2020) Add Share Today's Range$1.58Now: $1.58▼$1.5850-Day Range$1.32MA: $1.50▼$1.6852-Week Range$1.12Now: $1.58▼$1.85VolumeN/AAverage Volume6,925 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartHeadlinesSocial Media Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Medivir AB (publ). Previous Next 2.9 Community Rank Outperform VotesMedivir AB (publ) has received 16 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedivir AB (publ) has received 12 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedivir AB (publ) has received 57.14% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medivir AB (publ) and other stocks. Vote “Outperform” if you believe MVRBF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MVRBF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedivir AB (publ) does not currently pay a dividend.Dividend GrowthMedivir AB (publ) does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medivir AB (publ) insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.58 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry N/A Sub-IndustryN/A SectorN/A Current SymbolOTCMKTS:MVRBF Previous Symbol CUSIPN/A CIKN/A Webwww.medivir.com Phone46 8 54 68 31 00Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees13 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable OTC:MVRBF Rates by TradingView Receive MVRBF News and Ratings via Email Sign-up to receive the latest news and ratings for MVRBF and its competitors with MarketBeat's FREE daily newsletter. Medivir AB (publ) (OTCMKTS:MVRBF) Frequently Asked Questions How has Medivir AB (publ)'s stock been impacted by COVID-19 (Coronavirus)? Medivir AB (publ)'s stock was trading at $1.67 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MVRBF shares have decreased by 5.4% and is now trading at $1.58. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Medivir AB (publ)? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medivir AB (publ) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Medivir AB (publ). Has Medivir AB (publ) been receiving favorable news coverage? News coverage about MVRBF stock has trended neutral this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medivir AB (publ) earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutMedivir AB (publ). Who are Medivir AB (publ)'s key executives? Medivir AB (publ)'s management team includes the following people: Dr. Uli Hacksell, CEO, Pres & Director (Age 70)Mr. Magnus Christensen, Chief Financial Officer (Age 46)Dr. Christina Herder, Exec. VP & COO (Age 59)Mr. Fredrik Öberg, Chief Scientific Officer (Age 55)Dr. Linda Basse, Chief Medical Officer (Age 64) What is Medivir AB (publ)'s stock symbol? Medivir AB (publ) trades on the OTCMKTS under the ticker symbol "MVRBF." How do I buy shares of Medivir AB (publ)? Shares of MVRBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Medivir AB (publ)'s stock price today? One share of MVRBF stock can currently be purchased for approximately $1.58. What is Medivir AB (publ)'s official website? The official website for Medivir AB (publ) is www.medivir.com. How can I contact Medivir AB (publ)? The company can be reached via phone at 46 8 54 68 31 00. This page was last updated on 5/30/2020 by MarketBeat.com Staff
